{"id":"low-dose-naloxone","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Withdrawal symptoms (if opioid-dependent)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Naloxone is a competitive opioid receptor antagonist; at very low doses, it selectively blocks toll-like receptor 4 (TLR4) signaling and glial cell activation without fully antagonizing therapeutic opioid effects. This reduces neuroinflammation and glial-mediated pain amplification, potentially enhancing analgesia and reducing opioid tolerance when co-administered with standard opioids or used alone for chronic pain conditions.","oneSentence":"Low-dose naloxone blocks opioid receptors at sub-analgesic concentrations to enhance endogenous opioid signaling and reduce pain and inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:36.146Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic pain (in combination with opioids or as monotherapy)"},{"name":"Opioid-induced hyperalgesia and tolerance"}]},"trialDetails":[{"nctId":"NCT05430152","phase":"PHASE2","title":"Low-dose Naltrexone for Post-COVID Fatigue Syndrome","status":"COMPLETED","sponsor":"Luis Nacul","startDate":"2024-01-15","conditions":"Post-Viral Fatigue Syndrome","enrollment":160},{"nctId":"NCT07475546","phase":"PHASE3","title":"Combination Gerotherapeutic Interventions for Healthspan Improvement","status":"ACTIVE_NOT_RECRUITING","sponsor":"AgelessRx","startDate":"2025-07-23","conditions":"Healthspan Improvement, Aging, Longevity","enrollment":30},{"nctId":"NCT07469501","phase":"PHASE4","title":"Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-06","conditions":"Opioid Use Disorder, Fentanyl","enrollment":50},{"nctId":"NCT07224009","phase":"PHASE2","title":"Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)","status":"NOT_YET_RECRUITING","sponsor":"University of Arkansas","startDate":"2026-03","conditions":"Metastatic Prostate Cancer","enrollment":60},{"nctId":"NCT07285473","phase":"PHASE2","title":"Low-Dose Naltrexone For ME/CFS: Dose-Finding","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-04-01","conditions":"Myalgic Encephalomyelitis/Chronic Fatigue Syndrome","enrollment":75},{"nctId":"NCT07064564","phase":"PHASE1","title":"iSTEP-N 101b: Pharmacokinetics and Safety Study of Low- and High-Dose Naltrexone Implants vs Monthly Vivitrol in Healthy Volunteers","status":"NOT_YET_RECRUITING","sponsor":"Akyso Therapeutics, LLC","startDate":"2026-04-01","conditions":"Opioid Use Disorder","enrollment":33},{"nctId":"NCT03482479","phase":"PHASE2","title":"Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2019-02-04","conditions":"Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS), Giant Cell Arteritis","enrollment":60},{"nctId":"NCT07333638","phase":"PHASE2","title":"Phase II Clinical Study on the Efficacy and Safety of Naltrexone Implant in Patients With Alcohol Use Disorder","status":"COMPLETED","sponsor":"Shenzhen Sciencare Medical Industries Co., Ltd.","startDate":"2023-04-03","conditions":"AUD","enrollment":210},{"nctId":"NCT07079241","phase":"NA","title":"A Model to Save Lives Through a Volunteer First Responder Service Providing Antidote Treatment in Opioid Overdose","status":"RECRUITING","sponsor":"Region Skane","startDate":"2025-09-01","conditions":"Opioid Overdose","enrollment":1000},{"nctId":"NCT06306157","phase":"PHASE4","title":"Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome","status":"ENROLLING_BY_INVITATION","sponsor":"Hospital for Special Surgery, New York","startDate":"2024-01-02","conditions":"Complex Regional Pain Syndrome, Chronic Pain, Causalgia","enrollment":40},{"nctId":"NCT07221565","phase":"PHASE1, PHASE2","title":"Quantum-Synaptic Immunotherapy Mapping Using Low-Frequency Electromagnetic Resonance and Machine Learning-Based Cytokine Forecasting","status":"ENROLLING_BY_INVITATION","sponsor":"Truway Health, Inc.","startDate":"2025-10-23","conditions":"Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis","enrollment":120},{"nctId":"NCT06366724","phase":"PHASE2","title":"LIFT: Life Improvement Trial","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2024-09-10","conditions":"ME/CFS, Long COVID, PASC","enrollment":160},{"nctId":"NCT04600089","phase":"PHASE2","title":"Ketamine in Patients Undergoing TEVAR Procedures Receiving NCI","status":"RECRUITING","sponsor":"Sam Tyagi","startDate":"2020-12-08","conditions":"Descending Aortic Dissection, Postoperative Pain, Thoracoabdominal Aortic Aneurysm","enrollment":30},{"nctId":"NCT05450718","phase":"PHASE4","title":"Low-dose Buprenorphine Initiation for Opioid Use Disorder","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2024-11-11","conditions":"Opioid Use Disorder","enrollment":70},{"nctId":"NCT05944952","phase":"PHASE4","title":"Low-dose Versus a High-dose Sublingual Buprenorphine Induction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Friends Research Institute, Inc.","startDate":"2024-06-20","conditions":"Opioid Use Disorder","enrollment":40},{"nctId":"NCT07092618","phase":"PHASE2, PHASE3","title":"Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation","status":"RECRUITING","sponsor":"AgelessRx","startDate":"2024-12-17","conditions":"Longevity, GLP-1, Geroscience","enrollment":150},{"nctId":"NCT05537935","phase":"PHASE4","title":"Low Dose Naltrexone for Pain in Patients With HIV","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-04-28","conditions":"Human Immunodeficiency Virus, Chronic Neuropathic Pain","enrollment":60},{"nctId":"NCT04744883","phase":"EARLY_PHASE1","title":"Efficacy of Spinal Manipulation Therapy or Mindfulness-based Reduction Therapy on Patients With Chronic Low Back Pain","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rush University Medical Center","startDate":"2020-08-15","conditions":"Chronic Low-back Pain","enrollment":140},{"nctId":"NCT03066739","phase":"PHASE2","title":"Effect of Ultra-low Dose Naloxone on Remifentanil-Induced Hyperalgesia","status":"TERMINATED","sponsor":"University of California, Irvine","startDate":"2023-02-25","conditions":"Hyperalgesia","enrollment":8},{"nctId":"NCT04678895","phase":"PHASE2","title":"Low-Dose Naltrexone for the Treatment of Painful Diabetic Neuropathy","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2020-12-22","conditions":"Painful Diabetic Neuropathy","enrollment":35},{"nctId":"NCT04313972","phase":"PHASE4","title":"IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone","status":"TERMINATED","sponsor":"Endeavor Health","startDate":"2021-09-07","conditions":"Interstitial Cystitis, Painful Bladder Syndrome, Bladder Pain Syndrome","enrollment":3},{"nctId":"NCT05307627","phase":"","title":"The Effects of Low Dose Naltrexone (LDN) on Diseases of Aging","status":"WITHDRAWN","sponsor":"AgelessRx","startDate":"2022-03-14","conditions":"Aging","enrollment":""},{"nctId":"NCT04794790","phase":"EARLY_PHASE1","title":"Buprenorphine Induction for Fentanyl Dependent Opioid Users","status":"WITHDRAWN","sponsor":"Milton S. Hershey Medical Center","startDate":"2022-05-09","conditions":"Opioid Dependence Fentanyl","enrollment":""},{"nctId":"NCT05363514","phase":"PHASE4","title":"Low Dose Naltrexone Use in Patients With POTS","status":"NOT_YET_RECRUITING","sponsor":"University of Calgary","startDate":"2025-01","conditions":"Postural Orthostatic Tachycardia Syndrome","enrollment":80},{"nctId":"NCT04739995","phase":"PHASE4","title":"Cost-utility and Physiological Effects of LDN in Patients With Fibromyalgia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundació Sant Joan de Déu","startDate":"2022-06-01","conditions":"Randomized Controlled Trial","enrollment":99},{"nctId":"NCT03194555","phase":"PHASE2","title":"The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination","status":"COMPLETED","sponsor":"Allodynic Therapeutics, Inc","startDate":"2017-08-25","conditions":"Migraine With or Without Aura","enrollment":12},{"nctId":"NCT02806440","phase":"PHASE4","title":"Low Dose Naltrexone for Treatment of Pain in Patients With Fibromyalgia - Effect Via a Central Mechanism?","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2016-06","conditions":"Fibromyalgia","enrollment":58},{"nctId":"NCT06245902","phase":"PHASE2","title":"An Acute Migraine Factorial Study","status":"COMPLETED","sponsor":"Allodynic Therapeutics, Inc","startDate":"2017-02-18","conditions":"Migraine With or Without Aura","enrollment":92},{"nctId":"NCT04450316","phase":"PHASE2","title":"Low-dose Naltrexone for Bladder Pain Syndrome","status":"SUSPENDED","sponsor":"Stanford University","startDate":"2020-10-08","conditions":"Bladder Pain Syndrome, Interstitial Cystitis","enrollment":40},{"nctId":"NCT04034004","phase":"EARLY_PHASE1","title":"Chronic Low Back Pain and Meditation","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2021-01-01","conditions":"Pain","enrollment":88},{"nctId":"NCT04756128","phase":"PHASE2","title":"Impact of Colchicine and Low-dose Naltrexone on COVID-19","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2021-01-25","conditions":"Covid19","enrollment":142},{"nctId":"NCT05955313","phase":"PHASE2","title":"Effectiveness of Low-dose Naltrexone in Patients With Different Types of Vulvodynia","status":"RECRUITING","sponsor":"Medical University of Lublin","startDate":"2023-05-31","conditions":"Vulvodynia, Naltrexone, Quality of Life","enrollment":300},{"nctId":"NCT02187198","phase":"PHASE3","title":"Buprenorphine Treatment for Opioid Dependence","status":"COMPLETED","sponsor":"Yale University","startDate":"2015-03","conditions":"Opioid Dependence","enrollment":9},{"nctId":"NCT04604704","phase":"PHASE2","title":"Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome","status":"COMPLETED","sponsor":"AgelessRx","startDate":"2021-01-28","conditions":"Covid19, Long COVID-19, Post-COVID-19 Syndrome","enrollment":36},{"nctId":"NCT04270877","phase":"PHASE2","title":"Fibromyalgia and Naltrexone: The FINAL Study","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2021-01-06","conditions":"Fibromyalgia","enrollment":99},{"nctId":"NCT04052139","phase":"PHASE2","title":"St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Gabapentin","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2021-01-25","conditions":"Chronic Pain, Alcohol Use, Unspecified, HIV Infections","enrollment":45},{"nctId":"NCT04454281","phase":"PHASE1","title":"Topical Naloxone to Diagnose Ocular Pain","status":"COMPLETED","sponsor":"Seema Capoor","startDate":"2020-10-01","conditions":"Dry Eye Syndromes, Neuropathic Pain","enrollment":1},{"nctId":"NCT03970330","phase":"PHASE3","title":"Low-Dose Naltrexone in Combination With Standard Treatment in Women With Endometriosis","status":"TERMINATED","sponsor":"Milton S. Hershey Medical Center","startDate":"2020-01-16","conditions":"Endometriosis","enrollment":9},{"nctId":"NCT04604678","phase":"PHASE2","title":"Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19","status":"WITHDRAWN","sponsor":"AgelessRx","startDate":"2021-02","conditions":"Covid19","enrollment":""},{"nctId":"NCT02965768","phase":"NA","title":"Immune Effects of Low-dose Naltrexone in ME/CFS","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2016-01","conditions":"Fatigue Syndrome, Chronic","enrollment":""},{"nctId":"NCT03447782","phase":"PHASE1, PHASE2","title":"Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in Children","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2018-07-23","conditions":"New Daily Persistent Headache (NDPH)","enrollment":45},{"nctId":"NCT01650350","phase":"PHASE2","title":"Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer","status":"TERMINATED","sponsor":"Brown University","startDate":"2012-11","conditions":"Melanoma, Prostate Cancer, Renal Cancer","enrollment":7},{"nctId":"NCT04365985","phase":"PHASE2","title":"Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19","status":"TERMINATED","sponsor":"Corewell Health East","startDate":"2020-04-29","conditions":"COVID-19, Acute Respiratory Distress Syndrome, Severe Acute Respiratory Syndrome (SARS)","enrollment":70},{"nctId":"NCT04409041","phase":"PHASE2","title":"Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-09-01","conditions":"Lichen Planopilaris, Frontal Fibrosing Alopecia","enrollment":43},{"nctId":"NCT03201393","phase":"PHASE2","title":"Low-Dose Naltrexone and Acetaminophen Combination in the Treatment of Chronic Low Back Pain (ANODYNE-4)","status":"COMPLETED","sponsor":"Allodynic Therapeutics, Inc","startDate":"2017-08-15","conditions":"Chronic Low Back Pain, Lumbar Radiculopathy","enrollment":12},{"nctId":"NCT03061734","phase":"PHASE2","title":"Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine","status":"COMPLETED","sponsor":"Allodynic Therapeutics, Inc","startDate":"2017-02-18","conditions":"Migraine With or Without Aura","enrollment":92},{"nctId":"NCT03185143","phase":"PHASE2, PHASE3","title":"Low-Dose Naltrexone and Acetaminophen Combination and Sumatriptan in the Acute Treatment of Migraine With Nausea","status":"COMPLETED","sponsor":"Allodynic Therapeutics, Inc","startDate":"2017-06-27","conditions":"Migraine With and Without Aura","enrollment":36},{"nctId":"NCT04518618","phase":"NA","title":"Effect of Intrathecal Naloxone in the Incidence of Pruritis After C.S","status":"COMPLETED","sponsor":"Tanta University","startDate":"2020-09-11","conditions":"Pruritis","enrollment":96},{"nctId":"NCT04673812","phase":"NA","title":"Influence Of Low Dose Intrathecal Naloxone On Bupivacaine - Fentanyl Spinal Anaesthesia For Lower Limb Orthopedic Surgery In Elderly Patients","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2020-12-10","conditions":"Anesthesia, Spinal, Elderly","enrollment":92},{"nctId":"NCT03008590","phase":"PHASE2","title":"Low Dose Naltrexone for Chronic Pain From Arthritis","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2018-05-01","conditions":"Osteoarthritis, Arthritis, Rheumatoid, Arthritis, Psoriatic","enrollment":29},{"nctId":"NCT03768466","phase":"PHASE4","title":"Efficacy and Safety of Oxycodone/Naloxone (Targin®) in Persistent Moderate to Severe Low Back Pain Following NSAIDs Treatment","status":"COMPLETED","sponsor":"Mundipharma Korea Ltd","startDate":"2018-11-21","conditions":"Low Back Pain","enrollment":123},{"nctId":"NCT00129246","phase":"PHASE1, PHASE2","title":"Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain","status":"COMPLETED","sponsor":"Yale University","startDate":"2004-12","conditions":"Smoking, Nicotine Dependence","enrollment":40},{"nctId":"NCT03015246","phase":"PHASE1, PHASE2","title":"Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence","status":"COMPLETED","sponsor":"Wayne State University","startDate":"2016-12","conditions":"Heroin Dependence, Opioid Use Disorder","enrollment":26},{"nctId":"NCT02469077","phase":"NA","title":"Reduced Opioid Analgesic Requirements Via Improved Endogenous Opioid Function","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2015-08","conditions":"Chronic Pain","enrollment":117},{"nctId":"NCT03278886","phase":"PHASE1, PHASE2","title":"St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Nalmefene","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2018-07-03","conditions":"HIV Infection, Alcohol Use, Pain","enrollment":11},{"nctId":"NCT04502251","phase":"PHASE2, PHASE3","title":"LDN and tDCS in Fibromyalgia","status":"COMPLETED","sponsor":"Centro Universitario La Salle","startDate":"2018-08-01","conditions":"Fibromyalgia","enrollment":92},{"nctId":"NCT01214083","phase":"PHASE2","title":"N-acetylcysteine Plus Naltrexone for the Treatment of Alcohol Dependence","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2010-10-15","conditions":"Alcoholism","enrollment":111},{"nctId":"NCT04250792","phase":"PHASE1","title":"Efficacy of Low Dose Naltrexone in Psoriasis","status":"COMPLETED","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2019-01-01","conditions":"Psoriasis","enrollment":42},{"nctId":"NCT04115020","phase":"PHASE2","title":"Low Dose Naltrexone for Chronic Pain in Osteoarthritis and Inflammatory Arthritis","status":"WITHDRAWN","sponsor":"Brigham and Women's Hospital","startDate":"2020-01","conditions":"Osteoarthritis, Arthritis, Rheumatoid, Arthritis, Psoriatic","enrollment":""},{"nctId":"NCT03266445","phase":"PHASE4","title":"Effect of Buprenorphine/Naloxone Continuation on Pain Control and Opioid Use","status":"UNKNOWN","sponsor":"Massachusetts General Hospital","startDate":"2018-10-05","conditions":"Opioid-use Disorder, Pain, Acute, Surgery","enrollment":76},{"nctId":"NCT00743145","phase":"PHASE2","title":"Effects of Low-dose Naltrexone in Combination With a Range of Smoked Marijuana","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2008-05","conditions":"Marijuana Smoking","enrollment":23},{"nctId":"NCT00715117","phase":"PHASE2","title":"The Efficacy of Low Dose Naltrexone Therapy in Children With Crohn's Disease","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2008-07","conditions":"Crohn's Disease","enrollment":14},{"nctId":"NCT02176291","phase":"PHASE2","title":"Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine","status":"COMPLETED","sponsor":"Jordan F. Karp","startDate":"2014-08","conditions":"Depression, Major Depressive Disorder","enrollment":31},{"nctId":"NCT03372486","phase":"NA","title":"Effect of Ultra-low Dose Naloxone During Supraclavicular Brachial Plexus Block on Post-operative Opioi","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2017-12-18","conditions":"Upper Extremity Trauma","enrollment":64},{"nctId":"NCT00921765","phase":"PHASE4","title":"Reversal of Ketamine Pharmacodynamic Effects With Naloxone","status":"TERMINATED","sponsor":"Ullevaal University Hospital","startDate":"2009-12","conditions":"Pain","enrollment":3},{"nctId":"NCT01407575","phase":"PHASE3","title":"Buprenorphine for Treatment Resistant Depression","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2011-09","conditions":"Depression, Depressive Disorder, Depressive Disorder, Major","enrollment":13},{"nctId":"NCT02885948","phase":"PHASE4","title":"The Use of Low Dose Prophylactic Naloxone Infusion to Prevent Respiratory Depression With Intrathecal Morphine.","status":"COMPLETED","sponsor":"University College Dublin","startDate":"2016-04","conditions":"Respiratory Depression","enrollment":96},{"nctId":"NCT02107014","phase":"NA","title":"Low Dose Naltrexone (LDN) Immune Monitoring","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2014-03","conditions":"Fibromyalgia","enrollment":9},{"nctId":"NCT01571362","phase":"PHASE3","title":"A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-06","conditions":"Chronic Pain, Low Back Pain, Analgesia","enrollment":410},{"nctId":"NCT01874951","phase":"PHASE2","title":"Low-Dose Naltrexone (LDN) for Depression Relapse and Recurrence","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2013-06","conditions":"Major Depressive Disorder, Depression, Unipolar, Recurrence","enrollment":12},{"nctId":"NCT02559973","phase":"PHASE1","title":"Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2015-09","conditions":"Opioid Use Disorder","enrollment":47},{"nctId":"NCT00135759","phase":"PHASE2","title":"Addition of Naltrexone to Methadone Taper","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2005-04","conditions":"Heroin Dependence, Opioid-Related Disorders, Substance-Related Disorders","enrollment":174},{"nctId":"NCT03002961","phase":"PHASE1","title":"Single Ascending Dose Study of RBP-6000","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2012-07","conditions":"Opioid Use Disorder","enrollment":48},{"nctId":"NCT00710385","phase":"PHASE3","title":"Abuse Liability of Suboxone Versus Subutex","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2007-09","conditions":"Opioid-related Disorders","enrollment":19},{"nctId":"NCT02856087","phase":"NA","title":"The Effect of Ultra-low-dose Naloxone on Remifentanil-induced Postoperative Hyperalgesia - A Randomized Controlled Study","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2014-11","conditions":"Pain","enrollment":92},{"nctId":"NCT01690546","phase":"PHASE2","title":"Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence","status":"COMPLETED","sponsor":"Paolo Mannelli","startDate":"2012-09","conditions":"Opiate Dependence","enrollment":38},{"nctId":"NCT01838616","phase":"PHASE4","title":"Tapentadol Prolonged Release (PR) Versus Oxycodone/Naloxone Prolonged Release in Severe Chronic Low Back Pain With a Neuropathic Component.","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2013-04","conditions":"Back Pain, Low Back Pain, Neuropathic Pain","enrollment":367},{"nctId":"NCT01462227","phase":"NA","title":"Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia","status":"COMPLETED","sponsor":"Yale University","startDate":"2011-08","conditions":"Hypoglycemia","enrollment":17},{"nctId":"NCT00000299","phase":"PHASE2","title":"Rapid Opiate Detoxification and Naltrexone Induction Using Buprenorphine - 2","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2008-10","conditions":"Opioid-Related Disorders","enrollment":12},{"nctId":"NCT00855972","phase":"NA","title":"Low Dose Naltrexone for the Treatment of Juvenile Primary Fibromyalgia Syndrome","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2010-08","conditions":"Fibromyalgia","enrollment":""},{"nctId":"NCT00568555","phase":"NA","title":"Effects of Low Dose Naltrexone in Fibromyalgia","status":"COMPLETED","sponsor":"Stanford University","startDate":"2007-06","conditions":"Fibromyalgia, Persian Gulf Syndrome","enrollment":53},{"nctId":"NCT01303835","phase":"PHASE2","title":"Low Dose Naltrexone for Glioma Patients","status":"COMPLETED","sponsor":"Katy Peters","startDate":"2011-05","conditions":"Malignant Glioma","enrollment":110},{"nctId":"NCT01810185","phase":"PHASE2","title":"Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease","status":"WITHDRAWN","sponsor":"Santa Barbara Cottage Hospital","startDate":"2013-03","conditions":"Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis","enrollment":""},{"nctId":"NCT00105482","phase":"PHASE2","title":"Targeted Interventions for Weight-Concerned Smokers","status":"COMPLETED","sponsor":"Yale University","startDate":"2005-01","conditions":"Nicotine Dependence","enrollment":172},{"nctId":"NCT00669175","phase":"","title":"Safety and Efficacy of a Low Dose Naloxone Infusion in NICU Patients","status":"COMPLETED","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2008-02","conditions":"Opioid Tolerance, Pain","enrollment":25},{"nctId":"NCT01174914","phase":"PHASE2","title":"Effectiveness Study Low-Dose Naltrexone Versus ARV's for HIV+","status":"COMPLETED","sponsor":"The Ojai Foundation","startDate":"2008-03","conditions":"HIV Seropositivity","enrollment":171},{"nctId":"NCT00679458","phase":"NA","title":"Randomized, Double-Blind Cross-Over Trial Of Buprenorphine and Low-Dose Naloxone Versus Buprenorphine","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2008-09","conditions":"Pain","enrollment":12},{"nctId":"NCT00829777","phase":"PHASE1","title":"Safety Study of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects","status":"COMPLETED","sponsor":"California Pacific Medical Center Research Institute","startDate":"2009-03","conditions":"Opiate Addiction","enrollment":8},{"nctId":"NCT00501696","phase":"PHASE3","title":"A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2007-02","conditions":"Multiple Sclerosis","enrollment":80},{"nctId":"NCT00318162","phase":"PHASE1, PHASE2","title":"Trial of Low-Dose Naltrexone for Children With Pervasive Developmental Disorder (PDD)","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"","conditions":"Pervasive Developmental Disorder","enrollment":50},{"nctId":"NCT00286052","phase":"PHASE3","title":"Impact of Low Dose Naloxone on Fentanyl Requirements in Pediatric ICU Patients","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2002-12","conditions":"Opioid Tolerance","enrollment":128}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":99,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Low Dose Naloxone","genericName":"Low Dose Naloxone","companyName":"University of Texas Southwestern Medical Center","companyId":"university-of-texas-southwestern-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low-dose naloxone blocks opioid receptors at sub-analgesic concentrations to enhance endogenous opioid signaling and reduce pain and inflammation. Used for Chronic pain (in combination with opioids or as monotherapy), Opioid-induced hyperalgesia and tolerance.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}